These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

164 related items for PubMed ID: 21566199

  • 1. Crossover dose escalation study to assess safety, pharmacokinetics, and pharmacodynamics of single doses of R1663, an oral factor Xa inhibitor, in healthy male volunteers.
    Schmitt C, Pannier A, McIntyre C, Zandt H, Ciorciaro C, Winters K, Pepper T.
    J Clin Pharmacol; 2012 Apr; 52(4):499-510. PubMed ID: 21566199
    [Abstract] [Full Text] [Related]

  • 2. Safety, pharmacokinetics and pharmacodynamics of multiple ascending doses of R1663, an oral factor Xa inhibitor, in healthy young subjects coupled with exploration of influence of gender and age.
    Schmitt C, Charoin-Pannier A, McIntyre C, Zandt H, Ciorciaro C, Winters K, Pepper T.
    Thromb Haemost; 2012 Jul; 108(1):54-64. PubMed ID: 22552265
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59-7939, an oral, direct factor Xa inhibitor.
    Kubitza D, Becka M, Voith B, Zuehlsdorf M, Wensing G.
    Clin Pharmacol Ther; 2005 Oct; 78(4):412-21. PubMed ID: 16198660
    [Abstract] [Full Text] [Related]

  • 5. A randomised assessment of the pharmacokinetic, pharmacodynamic and safety interaction between apixaban and enoxaparin in healthy subjects.
    Barrett YC, Wang J, Song Y, Pursley J, Wastall P, Wright R, Lacreta F, Frost C.
    Thromb Haemost; 2012 May; 107(5):916-24. PubMed ID: 22398784
    [Abstract] [Full Text] [Related]

  • 6. The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects.
    Stangier J, Rathgen K, Stähle H, Gansser D, Roth W.
    Br J Clin Pharmacol; 2007 Sep; 64(3):292-303. PubMed ID: 17506785
    [Abstract] [Full Text] [Related]

  • 7. Safety, tolerability, pharmacokinetics, and pharmacodynamics of multiple doses of apixaban in healthy Japanese male subjects.
    Yamahira N, Frost C, Fukase H, Yu Z, Wang J, Pursley J, LaCreta F, Hiraoka M.
    Int J Clin Pharmacol Ther; 2014 Jul; 52(7):564-73. PubMed ID: 24725442
    [Abstract] [Full Text] [Related]

  • 8. Effects of the oral, direct factor xa inhibitor rivaroxaban on platelet-induced thrombin generation and prothrombinase activity.
    Graff J, von Hentig N, Misselwitz F, Kubitza D, Becka M, Breddin HK, Harder S.
    J Clin Pharmacol; 2007 Nov; 47(11):1398-407. PubMed ID: 17873238
    [Abstract] [Full Text] [Related]

  • 9. Assessment of laboratory assays to measure rivaroxaban--an oral, direct factor Xa inhibitor.
    Samama MM, Martinoli JL, LeFlem L, Guinet C, Plu-Bureau G, Depasse F, Perzborn E.
    Thromb Haemost; 2010 Apr; 103(4):815-25. PubMed ID: 20135059
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Clinical safety, tolerability, pharmacokinetics, and pharmacodynamics of the novel factor Xa inhibitor edoxaban in healthy volunteers.
    Ogata K, Mendell-Harary J, Tachibana M, Masumoto H, Oguma T, Kojima M, Kunitada S.
    J Clin Pharmacol; 2010 Jul; 50(7):743-53. PubMed ID: 20081065
    [Abstract] [Full Text] [Related]

  • 12. Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects.
    Eerenberg ES, Kamphuisen PW, Sijpkens MK, Meijers JC, Buller HR, Levi M.
    Circulation; 2011 Oct 04; 124(14):1573-9. PubMed ID: 21900088
    [Abstract] [Full Text] [Related]

  • 13. Pharmacodynamic markers in the early clinical assessment of otamixaban, a direct factor Xa inhibitor.
    Paccaly A, Ozoux ML, Chu V, Simcox K, Marks V, Freyburger G, Sibille M, Shukla U.
    Thromb Haemost; 2005 Dec 04; 94(6):1156-63. PubMed ID: 16411387
    [Abstract] [Full Text] [Related]

  • 14. Effect of apixaban, an oral and direct factor Xa inhibitor, on coagulation activity biomarkers following acute coronary syndrome.
    Becker RC, Alexander JH, Newby LK, Yang H, Barrett Y, Mohan P, Wang J, Harrington RA, Wallentin LC.
    Thromb Haemost; 2010 Nov 04; 104(5):976-83. PubMed ID: 20806117
    [Abstract] [Full Text] [Related]

  • 15. Safety, pharmacokinetics, and pharmacodynamics of PD 0348292, an oral, direct factor Xa inhibitor, after single and multiple dosings in healthy subjects.
    Xuan D, McBride S, Wastall P, Porcari A, DiCarlo L, Boyd RA.
    Clin Pharmacol Drug Dev; 2016 Jan 04; 5(1):13-26. PubMed ID: 27119575
    [Abstract] [Full Text] [Related]

  • 16. Phase I study of Solulin, a novel recombinant soluble human thrombomodulin analogue.
    van Iersel T, Stroissnig H, Giesen P, Wemer J, Wilhelm-Ogunbiyi K.
    Thromb Haemost; 2011 Feb 04; 105(2):302-12. PubMed ID: 21103657
    [Abstract] [Full Text] [Related]

  • 17. Bioequivalence of generic and branded subcutaneous enoxaparin: a single-dose, randomized-sequence, open-label, two-period crossover study in healthy Chinese male subjects.
    Feng L, Shen-Tu J, Liu J, Chen J, Wu L, Huang M.
    Clin Ther; 2009 Jul 04; 31(7):1559-67. PubMed ID: 19695405
    [Abstract] [Full Text] [Related]

  • 18. Clinical safety, tolerability, pharmacokinetics and pharmacodynamics of the novel factor Xa inhibitor DY-807f in healthy volunteers.
    Ogata K, Shimizu T, Masumoto H, Oguma T, Sugiyama N, Kunitada S.
    Thromb Res; 2015 Apr 04; 135(4):594-601. PubMed ID: 25700621
    [Abstract] [Full Text] [Related]

  • 19. Pharmacokinetics, pharmacodynamics and food effect of LB30870, a novel direct thrombin inhibitor, after single oral doses in healthy men.
    Kim J, Lee SH, Boyce M, Warrington S, Cho KH, Yoon SK, Park HD, Kim A.
    Xenobiotica; 2015 Apr 04; 45(8):663-71. PubMed ID: 25673087
    [Abstract] [Full Text] [Related]

  • 20. Direct and rapid inhibition of factor Xa by otamixaban: a pharmacokinetic and pharmacodynamic investigation in patients with coronary artery disease.
    Hinder M, Frick A, Jordaan P, Hesse G, Gebauer A, Maas J, Paccaly A.
    Clin Pharmacol Ther; 2006 Dec 04; 80(6):691-702. PubMed ID: 17178269
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.